BUFFALO GROVE -- Xellia Pharmaceuticals has signed an agreement with Civica Rx to manufacture Civica antibiotics, including Vancomycin and Daptomycin, for Civica's member health systems.
It is the first partnership for Utah-based Civica, which has committed to partnering with suppliers to deliver 14 essential generic medications this year to address chronic drug shortages. Shortages of these anti-infective medications are affecting patient care in hospitals across the United States, according to the company.
Denmark-based Xellia, with U.S. operations in Buffalo Grove, is expanding its manufacturing and sales capabilities within the U.S. and has a long-standing heritage of manufacturing with an emphasis on quality and security of supply. The company produces its own active pharmaceutical ingredients, as well as finished injectable drug products for serious or life-threatening bacterial and fungal infections.
The partnership with Xellia will help avoid drug shortages and enable the supply security Civica and its member health systems are seeking. Xellia will make medications for Civica under Xellia's Abbreviated New Drug Application and Civica labeling and New Drug Code.
"We thank Xellia for helping to lead the way in efforts to reduce chronic generic drug shortages in the U.S., including treatments for serious infections caused by bacteria that are resistant to other antibiotics," said Martin VanTrieste, president and CEO of Civica.